The global Primary Sclerosing Cholangitis (PSC) Market is expected to be worth US$ 151.07 million in 2023. Because of rising alcohol consumption, the overall demand for Primary Sclerosing Cholangitis (PSC) is expected to grow at a CAGR of 7.6% between 2023 and 2033, totaling around US$ 314.26 Million by 2033.
The Primary Sclerosing Cholangitis (PSC) market is expected to grow during the analysis period, owing to factors such as an increase in the incidence of liver diseases and an increase in alcohol consumption, according to Future Market Insights. The global incidence of liver disease in 2016 was 3.9 million, according to the Centers for Disease Control and Prevention. According to the World Health Organization (WHO), alcohol consumption is increasing the prevalence of liver cirrhosis in European countries. Furthermore, rising awareness campaigns and increased R&D investment for the development of new drug molecules are expected to drive the primary sclerosing cholangitis market during the forecast period.
Empower your business with insights and knowledge from our Sample Report! https://www.futuremarketinsights.com/reports/sample/rep-gb-16176
The rising prevalence of disorders associated with PSC, such as liver cancer and inflammatory bowel disease, is another factor that is expected to fuel therapeutic acceptance of effective pharmaceuticals to treat the condition, accelerating market growth. According to the World Journal of Gastroenterology, inflammatory bowel disease (IBD) is found in 50-80% of PSC patients, with ulcerative colitis (UC) accounting for 80-90 percent of these cases.
Key Takeaways:
The PSC market is expected to grow significantly over the next decade, driven by factors such as the increasing prevalence of PSC, rising awareness of the disease, and growing R&D investment.
The ursodiol drug type segment is expected to account for the largest share of the PSC market during the forecast period. This is due to the fact that ursodiol is the only FDA-approved drug for the treatment of PSC.
The off-label drugs segment is expected to account for the largest share of the PSC market based on treatment type during the forecast period. This is due to the fact that there are a number of off-label drugs that are used to treat PSC, such as budesonide and obeticholic acid.
North America is expected to account for the largest share of the PSC market based on region during the forecast period. This is due to the high prevalence of PSC in North America and the availability of advanced treatment options.
Get a Customized Scope to Match Your Need Ask an Expert! https://www.futuremarketinsights.com/customization-available/rep-gb-16176
Primary Sclerosing Cholangitis (PSC) Market: Competition Analysis
The FMI’s study presents a comprehensive analysis of global, regional, and country-level players active in the Primary Sclerosing Cholangitis (PSC) market. Competitive information detailed in the Primary Sclerosing Cholangitis (PSC) market report has been based on innovative product launches, distribution channels, local networks, industrial penetration, production methods, and revenue generation of each market player. Furthermore, growth strategies and mergers & acquisitions (M&A) activities associated with the players are enclosed in the Primary Sclerosing Cholangitis (PSC) market report.
Key players covered in the report include:
- Acorda Therapeutics, Inc.
- Gilead Sciences, Inc.
- NGM Biopharmaceuticals, Inc.
- Intercept Pharmaceuticals, Inc.
- Dr. Falk Pharma GmbH
- Allergan Plc.
- Shire Plc.
- Durect Corporation
- Conatus Pharmaceuticals, Inc.
- Sirnaomics, Inc.
- Shenzhen HighTide Biopharmaceutical Ltd
Key Segments Covered in the Primary Sclerosing Cholangitis (PSC) Industry Analysis:
Primary Sclerosing Cholangitis (PSC) Market by Drug:
- BTT1023
- GS-9674
- NGM282
- OCA
- Cenicriviroc
- LUM001
- DUR928
- norUDCA
- HTD1801
- IDN-7314
- STP705
Primary Sclerosing Cholangitis (PSC) Market by Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Elevate Your Awareness With Our Enlightening Methodology Insights! https://www.futuremarketinsights.com/request-report-methodology/rep-gb-16176
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
